Supreme Court to hear Medtronic's appeal of Boston Scientific's CRM patent win

May 20, 2013 by Brad Perriello

The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival Boston Scientific over cardiac rhythm management technology.

Supreme Court to hear Medtronic's appeal of Boston Scientific CRM patent win

The U.S. Supreme Court agreed to hear Medtronic's (NYSE:MDT) appeal of a lower court's decision that the medical device company infringes a cardiac rhythm therapy device patent owned by rival Boston Scientific (NYSE:BSX).

Last September the U.S Court of Appeals for the Federal Circuit overturned a Delaware court's decision that Medtronic hadn't infringed on Boston Scientific's patents, finding that the lower court used "a legally incorrect allocation of the burden of proof" and remanding the case for reconsideration.

Medtronic appealed that decision, and today the Supremes granted certiorari, meaning the 9 justices will take up the issue during the high court's next session beginning in October.

Sign up to get our free newsletters delivered right to your inbox.

The long-running dispute concerns fundamental CRT technology covered in a pair of patents issued to CRM pioneer Dr. Morton Mower, credited with inventing the technology that ultimately became known as a cardiac resynchronization therapy device.